
Otonomy OTIC
Quarterly report 2022-Q3
added 11-10-2022
Otonomy Depreciation & Amortization 2011-2026 | OTIC
Annual Depreciation & Amortization Otonomy
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 856 K | 1.06 M | 1.15 M | 1.19 M | 1.29 M | 708 K | 358 K | 213 K | 257 K | 192 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 192 K | 727 K |
Quarterly Depreciation & Amortization Otonomy
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 668 K | - | 195 K | - | 648 K | - | 221 K | - | 843 K | 569 K | 286 K | - | 854 K | 565 K | 276 K | - | 892 K | 594 K | 295 K | - | 923 K | 592 K | 283 K | - | 496 K | 320 K | 152 K | - | 212 K | 124 K | 60 K | - | 152 K | 100 K | 49 K | - | 194 K | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 923 K | 49 K | 406 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Esperion Therapeutics
ESPR
|
105 K | $ 3.13 | 0.55 % | $ 651 M | ||
|
Exelixis
EXEL
|
29.1 M | $ 48.2 | 8.51 % | $ 13.1 B | ||
|
Fortress Biotech
FBIO
|
403 K | $ 2.53 | 2.85 % | $ 70.6 M | ||
|
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | ||
|
Genprex
GNPX
|
6.69 K | $ 0.91 | 2.24 % | $ 849 K | ||
|
Ionis Pharmaceuticals
IONS
|
10 M | $ 77.0 | 2.33 % | $ 12.3 B | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Kymera Therapeutics
KYMR
|
8.31 M | $ 85.79 | 3.72 % | $ 7.25 B | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
35.2 M | $ 231.58 | -0.31 % | $ 4.24 B | ||
|
INmune Bio
INMB
|
84 K | $ 1.54 | - | $ 38.1 M | ||
|
Liquidia Corporation
LQDA
|
1.53 M | $ 41.64 | 3.75 % | $ 3.58 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
920 K | $ 22.58 | 1.03 % | $ 3.74 B | ||
|
Mirum Pharmaceuticals
MIRM
|
24.2 M | $ 107.36 | 1.46 % | $ 5.39 B | ||
|
MannKind Corporation
MNKD
|
12.3 M | $ 3.61 | 26.17 % | $ 1.1 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.46 | -1.14 % | $ 5.7 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 24.0 | 2.46 % | $ 3.05 B | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B |